Rallybio Corp has declared a special cash distribution of approximately $82.7 million to its shareholders. This announcement comes as part of the company's merger with Avenzo Therapeutics, which is expected to enhance shareholder value. The distribution is significant, estimated at $13.56 per share, and reflects Rallybio's commitment to its investors.
The cash distribution is scheduled to be paid to stockholders and pre-funded warrant holders of record as of November 5, 2026. The payment will occur on November 13, 2026, pending the approval of the merger by the company's shareholders. This strategic move is poised to attract attention within the pharmaceutical preparations industry, as it demonstrates an effective approach to enhancing shareholder returns.
Background
Rallybio Corp, incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC: 2834). The company trades under the ticker symbol RLYB on the Nasdaq exchange. Rallybio focuses on developing therapies for rare diseases and has been actively pursuing growth through strategic mergers and acquisitions.
What the Filing Says
In the recent SEC filing, Rallybio's board of directors declared the special cash distribution in connection with the merger with Avenzo Therapeutics. The filing states, "The Cash Distribution, which the Company estimates to be an aggregate of $82.7 million, or an estimated $13.56 per share, will be payable in cash to the stockholders and pre-funded warrant holders of record as of November 5, 2026." This reflects the company's good faith calculation of its net cash position prior to the merger closing.
Impact
The cash distribution will directly benefit Rallybio's shareholders, providing them with immediate financial returns. Additionally, the merger with Avenzo Therapeutics could lead to enhanced operational efficiencies and broadened therapeutic capabilities for Rallybio, potentially impacting its competitive positioning in the pharmaceutical preparations market.
What's Next
The cash distribution is contingent upon receiving the required stockholder vote at the company's annual meeting scheduled for November 4, 2026. If approved, the merger is expected to close shortly thereafter, on or about November 6, 2026. The company will continue to provide updates as the situation progresses.